<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.comparative-hepatology.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Comparative Hepatology - Most accessed articles</title>
        <link>http://www.comparative-hepatology.com</link>
        <description>The most accessed research articles published by Comparative Hepatology</description>
        <dc:date>2012-04-23T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/2/1/7" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/11/1/1" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/2/1/4" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/1/1/1" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/3/1/8" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/10/1/9" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/6/1/8" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/9/1/1" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/2/1/5" />
                                <rdf:li rdf:resource="http://www.comparative-hepatology.com/content/10/1/4" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.comparative-hepatology.com/content/2/1/7">
        <title>FNH-like nodules: Possible precursor lesions in patients with focal nodular hyperplasia (FNH)</title>
        <description>Background:
The typical lesion of focal nodular hyperplasia (FNH) is a benign tumor-like mass characterized by hepatocytic nodules separated by fibrous bands. The solitary central artery with high flow and the absent portal vein give the lesions their characteristic radiological appearance. The great majority of cases seen in daily practice conform to the above description. Additional small nodules (from 1-2 up to 15-20 mm in diameter) detected by imaging techniques or on macroscopic examination may be difficult to identify as representing FNH if they lack the key features of FNH as defined in larger lesions. The aim of this study was to characterize these small nodules, and to compare their characteristics with those of typical lesions of FNH present in the same specimens.
Results:
Eight patients underwent hepatic resections for the removal of a mass lesion (&quot;nodule&quot;) diagnosed as: FNH (1 patient); nodules of unknown nature (5 patients); or nodules thought to be adenoma or hepatocellular carcinoma (2 patients). Six nodules out of 9 discovered by imaging techniques met histopathological criteria for the diagnosis of typical FNH, at least in parts of the nodule; 2 nodules corresponded to a minor form of FNH (&quot;subtle FNH&quot;) and one nodule to a steatotic area. Although FNH was thought to be found in a normal or nearly normal liver, this study revealed that, in addition, there were various types of small FNH-like nodules and vascular abnormalities in the liver with typical FNH nodule. The various types of small FNH-like nodules (n = 8, diameter 2 to 20 mm) consisted of the association to various degrees of numerous and/or enlarged arteries in portal tracts or in septa, with hyperplastic foci, slight ductular reaction, and regions of sinusoidal dilatation, accompanied by thin fibrous bands. Vascular abnormalities consisted of unpaired arteries, portal tracts with arteries larger than the associated bile duct, and regions of sinusoidal dilatation.
Conclusions:
Although these small nodules can be considered as insufficient type or abortive forms of FNH, or adenoma, they can be precursors of the large mass lesions in which FNH was recognized and defined.</description>
        <link>http://www.comparative-hepatology.com/content/2/1/7</link>
                <dc:creator>Sebastien Lepreux</dc:creator>
                <dc:creator>Christophe Laurent</dc:creator>
                <dc:creator>Charles Balabaud</dc:creator>
                <dc:creator>Paulette Bioulac-Sage</dc:creator>
                <dc:source>Comparative Hepatology 2003, null:7</dc:source>
        <dc:date>2003-06-26T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-2-7</dc:identifier>
                                <prism:require>/content/figures/1476-5926-2-7-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2003-06-26T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/11/1/1">
        <title>Severe diabetes and leptin resistance cause differential hepatic and renal transporter expression in mice</title>
        <description>Background:
Type-2 Diabetes is a major health concern in the United States and other Westernized countries, with prevalence increasing yearly. There is a need to better model and predict adverse drug reactions, drug-induced liver injury, and drug efficacy in this population. Because transporters significantly contribute to drug clearance and disposition, it is highly significant to determine whether a severe diabetes phenotype alters drug transporter expression, and whether diabetic mouse models have altered disposition of acetaminophen (APAP) metabolites.
Results:
Transporter mRNA and protein expression were quantified in livers and kidneys of adult C57BKS and db/db mice, which have a severe diabetes phenotype due to a lack of a functional leptin receptor. The urinary excretion of acetaminophen-glucuronide, a substrate for multidrug resistance-associated proteins transporters was also determined. The mRNA expression of major uptake transporters, such as organic anion transporting polypeptide Slco1a1 in liver and kidney, 1a4 in liver, and Slc22a7 in kidney was decreased in db/db mice. In contrast, Abcc3 and 4 mRNA and protein expression was more than 2 fold higher in db/db male mouse livers as compared to C57BKS controls. Urine levels of APAP-glucuronide, -sulfate, and N-acetyl cysteine metabolites were higher in db/db mice.
Conclusion:
A severe diabetes phenotype/presentation significantly altered drug transporter expression in liver and kidney, which corresponded with urinary APAP metabolite levels.</description>
        <link>http://www.comparative-hepatology.com/content/11/1/1</link>
                <dc:creator>Vijay More</dc:creator>
                <dc:creator>Xia Wen</dc:creator>
                <dc:creator>Paul Thomas</dc:creator>
                <dc:creator>Lauren Aleksunes</dc:creator>
                <dc:creator>Angela Slitt</dc:creator>
                <dc:source>Comparative Hepatology 2012, null:1</dc:source>
        <dc:date>2012-04-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-11-1</dc:identifier>
                                <prism:require>/content/figures/1476-5926-11-1-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2012-04-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/2/1/4">
        <title>Eggshell and egg yolk proteins in fish: hepatic proteins for the next generation: oogenetic, population, and evolutionary implications of endocrine disruption</title>
        <description>The oocyte is the starting point for a new generation. Most of the machinery for DNA and protein synthesis needed for the developing embryo is made autonomously by the fertilized oocyte. However, in fish and in many other oviparous vertebrates, the major constituents of the egg, i.e. yolk and eggshell proteins, are synthesized in the liver and transported to the oocyte for uptake. Vitellogenesis, the process of yolk protein (vitellogenin) synthesis, transport, and uptake into the oocyte, and zonagenesis, the synthesis of eggshell zona radiata proteins, their transport and deposition by the maturing oocyte, are important aspects of oogenesis. The many molecular events involved in these processes require tight, coordinated regulation that is under strict endocrine control, with the female sex steroid hormone estradiol-17&#946; in a central role. The ability of many synthetic chemical compounds to mimic this estrogen can lead to unscheduled hepatic synthesis of vitellogenin and zona radiata proteins, with potentially detrimental effects to the adult, the egg, the developing embryo and, hence, to the recruitment to the fish population. This has led to the development of specific and sensitive assays for these proteins in fish, and the application of vitellogenin and zona radiata proteins as informative biomarkers for endocrine disrupting effects of chemicals and effluents using fish as test organisms. The genes encoding these important reproductive proteins are conserved in the animal kingdom and are products of several hundred million years of evolution.</description>
        <link>http://www.comparative-hepatology.com/content/2/1/4</link>
                <dc:creator>Augustine Arukwe</dc:creator>
                <dc:creator>Anders Goksoyr</dc:creator>
                <dc:source>Comparative Hepatology 2003, null:4</dc:source>
        <dc:date>2003-03-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-2-4</dc:identifier>
                                <prism:require>/content/figures/1476-5926-2-4-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2003-03-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/1/1/1">
        <title>Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review</title>
        <description>This review provides a detailed overview of the current state of knowledge about the ultrastructure and dynamics of liver sinusoidal endothelial fenestrae. Various aspects of liver sinusoidal endothelial fenestrae regarding their structure, origin, species specificity, dynamics and formation will be explored. In addition, the role of liver sinusoidal endothelial fenestrae in relation to lipoprotein metabolism, fibrosis and cancer will be approached.</description>
        <link>http://www.comparative-hepatology.com/content/1/1/1</link>
                <dc:creator>Filip Braet</dc:creator>
                <dc:creator>Eddie Wisse</dc:creator>
                <dc:source>Comparative Hepatology 2002, null:1</dc:source>
        <dc:date>2002-08-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-1-1</dc:identifier>
                                <prism:require>/content/figures/1476-5926-1-1-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2002-08-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/3/1/8">
        <title>Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C</title>
        <description>Summary
Background:
Recent studies strongly suggest that due to the limitations and risks of biopsy, as well as the improvement of the diagnostic accuracy of biochemical markers, liver biopsy should no longer be considered mandatory in patients with chronic hepatitis C. In 2001, FibroTest ActiTest (FT-AT), a panel of biochemical markers, was found to have high diagnostic value for fibrosis (FT range 0.00&#8211;1.00) and necroinflammatory histological activity (AT range 0.00&#8211;1.00). The aim was to summarize the diagnostic value of these tests from the scientific literature; to respond to frequently asked questions by performing original new analyses (including the range of diagnostic values, a comparison with other markers, the impact of genotype and viral load, and the diagnostic value in intermediate levels of injury); and to develop a system of conversion between the biochemical and biopsy estimates of liver injury.
Results:
A total of 16 publications were identified. An integrated database was constructed using 1,570 individual data, to which applied analytical recommendations. The control group consisted of 300 prospectively studied blood donors. For the diagnosis of significant fibrosis by the METAVIR scoring system, the areas under the receiver operating characteristics curves (AUROC) ranged from 0.73 to 0.87. For the diagnosis of significant histological activity, the AUROCs ranged from 0.75 to 0.86. At a cut off of 0.31, the FT negative predictive value for excluding significant fibrosis (prevalence 0.31) was 91%. At a cut off of 0.36, the ActiTest negative predictive value for excluding significant necrosis (prevalence 0.41) was 85%. In three studies there was a direct comparison in the same patients of FT versus other biochemical markers, including hyaluronic acid, the Forns index, and the APRI index. All the comparisons favored FT (P &lt; 0.05). There were no differences between the AUROCs of FT-AT according to genotype or viral load. The AUROCs of FT-AT for consecutive stages of fibrosis and grades of necrosis were the same for both moderate and extreme stages and grades. A conversion table was constructed between the continuous FT-AT values (0.00 to 1.00) and the expected semi-quantitative fibrosis stages (F0 to F4) and necrosis grades (A0 to A3).
Conclusions:
Based on these results, the use of the biochemical markers of liver fibrosis (FibroTest) and necrosis (ActiTest) can be recommended as an alternative to liver biopsy for the assessment of liver injury in patients with chronic hepatitis C. In clinical practice, liver biopsy should be recommended only as a second line test, i.e., in case of high risk of error of biochemical tests.</description>
        <link>http://www.comparative-hepatology.com/content/3/1/8</link>
                <dc:creator>Thierry Poynard</dc:creator>
                <dc:creator>Francoise Imbert-Bismut</dc:creator>
                <dc:creator>Mona Munteanu</dc:creator>
                <dc:creator>Djamila Messous</dc:creator>
                <dc:creator>Robert Myers</dc:creator>
                <dc:creator>Dominique Thabut</dc:creator>
                <dc:creator>Vlad Ratziu</dc:creator>
                <dc:creator>Anne Mercadier</dc:creator>
                <dc:creator>Yves Benhamou</dc:creator>
                <dc:creator>Bernard Hainque</dc:creator>
                <dc:source>Comparative Hepatology 2004, null:8</dc:source>
        <dc:date>2004-09-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-3-8</dc:identifier>
                                <prism:require>/content/figures/1476-5926-3-8-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2004-09-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/10/1/9">
        <title>Autoimmune liver disease - Are there spectra that we do not know?</title>
        <description>Autoimmune liver diseases (AILDs) are common leading causes for liver cirrhosis and terminal stage of liver disease. They have variable prevalence among patients with liver disease and have two major clinical and biochemical presentations. Autoimmune hepatitis (AIH) is the typical example of hepatocellular AILD, but it can also be presented under a cholestatic pattern. AIH has a scoring diagnostic system and respond in most cases to the treatment with prednisolone and azathioprine. Primary biliary cirrhosis (PBC) is the second most common AILD, with a cholestatic presentation and characterized by positive antimitochondrial antibody (AMA). It has an excellent response and long term outcome with the administration of ursodeoxycholic acid (UDCA). Another AILD that is thought to be a variant of PBC is the autoimmune cholangitis, being a disease that has biochemical and histological features similar to PBC; but the AMA is negative. Primary sclerosing cholangitis (PSC) is a rare entity of AILD that has a cholestatic presentation and respond poorly to the treatment, with the ultimate progression to advance liver cirrhosis in most patients. Other forms of AILD include the overlap syndromes (OS), which are diseases with mixed immunological and histological patterns of two AILD; the most commonly recognized one is AIH-PBC overlap (AIH-PSC overlap is less common). The treatment of OS involves the trial of UDCA and different immunosuppressants. Here we present three case reports of unusual forms of chronic liver diseases that most likely represent AILD. The first two patients had a cholestatic picture, whereas the third one had a hepatocellular picture at presentation. We discussed their biochemical, immunological and histological features as well as their response to treatment and their outcomes. Then, we compared them with other forms of AILD.</description>
        <link>http://www.comparative-hepatology.com/content/10/1/9</link>
                <dc:creator>Hind Fallatah</dc:creator>
                <dc:creator>Hisham Akbar</dc:creator>
                <dc:source>Comparative Hepatology 2011, null:9</dc:source>
        <dc:date>2011-09-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-10-9</dc:identifier>
                                <prism:require>/content/figures/1476-5926-10-9-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2011-09-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/6/1/8">
        <title>Major HGF-mediated regenerative pathways are similarly affected in human and canine cirrhosis</title>
        <description>Background:
The availability of non-rodent animal models for human cirrhosis is limited. We investigated whether privately-owned dogs (Canis familiaris) are potential model animals for liver disease focusing on regenerative pathways. Several forms of canine hepatitis were examined: Acute Hepatitis (AH), Chronic Hepatitis (CH), Lobular Dissecting Hepatitis (LDH, a specific form of micronodulair cirrhosis), and Cirrhosis (CIRR). Canine cirrhotic samples were compared to human liver samples from cirrhotic stages of alcoholic liver disease (hALC) and chronic hepatitis C infection (hHC).
Results:
Canine specific mRNA expression of the regenerative hepatocyte growth factor (HGF) signaling pathway and relevant down-stream pathways were measured by semi-quantitative PCR and Western blot (STAT3, PKB, ERK1/2, and p38-MAPK). In all canine groups, levels of c-MET mRNA (proto-oncogenic receptor for HGF) were significantly decreased (p &lt; 0.05). Surprisingly, ERK1/2 and p38-MAPK were increased in CH and LDH. In the human liver samples Western blotting indicated a high homology of down-stream pathways between different etiologies (hALC and hHC). Similarly activated pathways were found in CIRR, hALC, and hHC.
Conclusion:
In canine hepatitis and cirrhosis the major regenerative downstream pathways were activated. Signaling pathways are similarly activated in human cirrhotic liver samples, irrespective of the differences in etiology in the human samples (alcohol abuse and HCV-infection). Therefore, canine hepatitis and cirrhosis could be an important clinical model to evaluate novel interventions prior to human clinical trials.</description>
        <link>http://www.comparative-hepatology.com/content/6/1/8</link>
                <dc:creator>Bart Spee</dc:creator>
                <dc:creator>Brigitte Arends</dc:creator>
                <dc:creator>Ted van den Ingh</dc:creator>
                <dc:creator>Tania Roskams</dc:creator>
                <dc:creator>Jan Rothuizen</dc:creator>
                <dc:creator>Louis Penning</dc:creator>
                <dc:source>Comparative Hepatology 2007, null:8</dc:source>
        <dc:date>2007-07-31T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-6-8</dc:identifier>
                                <prism:require>/content/figures/1476-5926-6-8-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2007-07-31T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/9/1/1">
        <title>Serum levels of soluble Fas, soluble tumor necrosis factor-receptor II, interleukin-2 receptor and interleukin-8 as early predictors of hepatocellular carcinoma in Egyptian patients with hepatitis C virus genotype-4</title>
        <description>Background:
Liver disease progression from chronic hepatitis C virus (HCV) infection to hepatocellular carcinoma (HCC) is associated with an imbalance between T-helper 1 and T-helper 2 cytokines. Evaluation of cytokines as possible candidate biomarkers for prediction of HCC was performed using soluble Fas (sFas), soluble tumor necrosis factor receptor-II (sTNFR-II), interleukin-2 receptor (IL-2R) and interleukin-8 (IL-8).
Results:
The following patients were recruited: 79 with HCV infection, 30 with HCC, 32 with chronic liver disease associated with elevated liver enzyme levels (with or without cirrhosis) in addition to 17 with chronic HCV with persistent normal alanine aminotransferase levels (PNALT). Nine normal persons negative either for HCV or for hepatitis B virus were included as a control group. All persons were tested for sFas, sTNFR-II, IL-2R and IL-8 in their serum by quantitative ELISA. HCC patients had higher levels of liver enzymes but lower log-HCV titer when compared to the other groups. HCC patients had also significantly higher levels of sFas, sTNFR-II and IL-2R and significantly lower levels of IL-8 when compared to the other groups. Exclusion of HCC among patients having PNALT could be predicted with 90% sensitivity and 70.6% specificity when sTNFR-II is &#8805; 389 pg/ml or IL-8 is &lt; 290 pg/ml.
Conclusions:
Serum TNFR-II, IL-2R&#945; and IL-8, may be used as combined markers in HCV-infected cases for patients at high risk of developing HCC; further studies, however, are mandatory to check these findings before their application at the population level.</description>
        <link>http://www.comparative-hepatology.com/content/9/1/1</link>
                <dc:creator>Abdel-Rahman Zekri</dc:creator>
                <dc:creator>Hanaa Alam El-Din</dc:creator>
                <dc:creator>Abeer Bahnassy</dc:creator>
                <dc:creator>Naglaa Zayed</dc:creator>
                <dc:creator>Waleed Mohamed</dc:creator>
                <dc:creator>Suzan El-Masry</dc:creator>
                <dc:creator>Sayed Gouda</dc:creator>
                <dc:creator>Gamal Esmat</dc:creator>
                <dc:source>Comparative Hepatology 2010, null:1</dc:source>
        <dc:date>2010-01-05T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-9-1</dc:identifier>
                                <prism:require>/content/figures/1476-5926-9-1-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>1</prism:startingPage>
        <prism:publicationDate>2010-01-05T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/2/1/5">
        <title>Animal models of copper-associated liver disease</title>
        <description>Recent advances in molecular biology have made possible the identification of genetic defects responsible for Wilson&apos;s disease, Indian childhood cirrhosis and copper toxicosis in Long Evans Cinnamon rats, toxic milk mice, and Bedlington terriers. The Wilson&apos;s disease gene is localized on human chromosome 13 and codes for ATP7B, a copper transporting P-type ATPase. A genetic defect similar to that of Wilson&apos;s disease occurs in Long Evans Cinnamon rats and toxic milk mice. Familial copper storage disorders in Bedlington and West Highland white terriers are associated with early subclinical disease, and copper accumulation with subsequent liver injury culminating in cirrhosis. The canine copper toxicosis locus in Bedlington terriers has been mapped to canine chromosome region CFA 10q26. Recently, a mutated MURR1 gene was discovered in Bedlington terriers affected with the disease. Idiopathic childhood cirrhosis is biochemically similar to copper toxicosis in Bedlington terriers, but clinically much more severe. Both conditions are characterized by the absence of neurologic damage and Kayser-Fleisher rings, and normal ceruloplasmin levels. A recent study added North Ronaldsay sheep to the list of promising animal models to study Indian childhood cirrhosis. Morphologic similarities between the two conditions include periportal to panlobular copper retention and liver changes varying from active hepatitis to panlobular pericellular fibrosis, and cirrhosis. Certain copper-associated disorders, such as chronic active hepatitis in Doberman pinschers and Skye terrier hepatitis are characterized by copper retention secondary to the underlying disease, thus resembling primary biliary cirrhosis in humans. Copper-associated liver disease has increasingly being recognized in Dalmatians. Copper-associated liver diseases in Dalmatians and Long Evans Cinnamom rats share many morphologic features. Fulminant hepatic failure in Dalmatians is characterized by high serum activities of alanine aminotransferase and aspartate aminotransferase, and severe necrosis of centrilobular areas (periacinar, zone 3) hepatocytes. Macrophages and surviving hepatocytes contain copper-positive material. Liver disease associated with periacinar copper accumulation has also been described in Siamese cats. Many questions regarding copper metabolism in mammals, genetic background, pathogenesis and treatment of copper-associated liver diseases remain to be answered. This review describes the similarities between the clinico-pathological features of spontaneous copper-associated diseases in humans and domestic animals.</description>
        <link>http://www.comparative-hepatology.com/content/2/1/5</link>
                <dc:creator>I Carmen Fuentealba</dc:creator>
                <dc:creator>Enrique Aburto</dc:creator>
                <dc:source>Comparative Hepatology 2003, null:5</dc:source>
        <dc:date>2003-04-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-2-5</dc:identifier>
                                <prism:require>/content/figures/1476-5926-2-5-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2003-04-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.comparative-hepatology.com/content/10/1/4">
        <title>Characterization of chronic HCV infection-induced apoptosis</title>
        <description>Background:
To understand the complex and largely not well-understood apoptotic pathway and immune system evasion mechanisms in hepatitis C virus (HCV)-associated hepatocellular carcinoma (HCC) and HCV associated chronic hepatitis (CH), we studied the expression patterns of a number of pro-apoptotic and anti-apoptotic genes (Fas, FasL, Bcl-2, Bcl-xL and Bak) in HepG2 cell line harboring HCV- genotype-4 replication. For confirmation, we also assessed the expression levels of the same group of genes in clinical samples obtained from 35 HCC and 34 CH patients.
Methods:
Viral replication was assessed in the tissue culture medium by RT-PCR, quantitative Real-Time PCR (qRT-PCR); detection of HCV core protein by western blot and inhibition of HCV replication with siRNA. The expression level of Fas, FasL, Bcl-2, Bcl-xL and Bak was assessed by immunohistochemistry and RT-PCR whereas caspases 3, 8 and 9 were assessed by colorimetric assay kits up to 135 days post infection.
Results:
There was a consistent increase in apoptotic activity for the first 4 weeks post-CV infection followed by a consistent decrease up to the end of the experiment. The concordance between the changes in the expression levels of Fas, FasL, Bcl-2, Bcl-xL and Bak in vitro and in situ was statistically significant (p &lt; 0.05). Fas was highly expressed at early stages of infection in cell lines and in normal control liver tissues followed by a dramatic reduction post-HCV infection and an increase in the expression level of FasL post HCV infection. The effect of HCV infection on other apoptotic proteins started very early post-infection, suggesting that hepatitis C modulating apoptosis by modulating intracellular pro-apoptotic signals.
Conclusions:
Chronic HCV infection differently modulates the apoptotic machinery during the course of infection, where the virus induces apoptosis early in the course of infection, and as the disease progresses apoptosis is modulated. This study could open a new opportunity for understanding the various signaling of apoptosis and in the developing a targeted therapy to inhibit viral persistence and HCC development.</description>
        <link>http://www.comparative-hepatology.com/content/10/1/4</link>
                <dc:creator>Abdel-Rahman Zekri</dc:creator>
                <dc:creator>Abeer Bahnassy</dc:creator>
                <dc:creator>Mohamed Hafez</dc:creator>
                <dc:creator>Zeinab Hassan</dc:creator>
                <dc:creator>Mahmoud Kamel</dc:creator>
                <dc:creator>Samah Loutfy</dc:creator>
                <dc:creator>Ghada Sherif</dc:creator>
                <dc:creator>Abdel-Rahman El-Zayadi</dc:creator>
                <dc:creator>Sayed Daoud</dc:creator>
                <dc:source>Comparative Hepatology 2011, null:4</dc:source>
        <dc:date>2011-07-23T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1476-5926-10-4</dc:identifier>
                                <prism:require>/content/figures/1476-5926-10-4-toc.gif</prism:require>
                <prism:publicationName>Comparative Hepatology</prism:publicationName>
        <prism:issn>1476-5926</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2011-07-23T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

